Ovarian carcinoma (high-grade serous predominant) · line 2 · Niraparib maintenance (HRD+ recurrent platinum-sensitive ovarian, NOVA / PRIMA)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	2
Track	aggressive
Linked regimen	`REG-NIRAPARIB-MAINT-OVARIAN`

ID	`IND-OVARIAN-MAINT-PARPI-HRD-NIRAPARIB`
Type	Indication
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-OVARIAN`
Sources	`SRC-ESMO-OVARIAN-2024` `SRC-NCCN-OVARIAN-2025` `SRC-NOVA-MIRZA-2016` `SRC-PRIMA-GONZALEZ-MARTIN-2019`

Notes

ESCAT IA (HRD+). Niraparib 2L+ maintenance — preferred when HRD+ and BRCA-WT, or BRCA-status unknown. Individualized starting dose mandatory.

Used By

Algorithms

ALGO-OVARIAN-2L - ALGO-OVARIAN-2L

Handbook Chapters

HB-OVARIAN-MAINTENANCE-1L - Advanced ovarian cancer: HRD/BRCA first-line maintenance reasoning

Handbook Questions

HQ-OVARIAN-MAINTENANCE-1L-002 - HQ-OVARIAN-MAINTENANCE-1L-002

Indication

IND-OVARIAN-2L-PLAT-SENS-CARBO-GEM-BEV - IND-OVARIAN-2L-PLAT-SENS-CARBO-GEM-BEV
IND-OVARIAN-2L-PLAT-SENS-CARBO-PLD-BEV - IND-OVARIAN-2L-PLAT-SENS-CARBO-PLD-BEV